DNA-repair pathway inhibitors for the treatment of ovarian cancer

Igor Martinek, Krishnayan Haldar, Kezia Gaitskell, Andrew Bryant, Shibani Nicum, Sean Kehoe, Jo Morrison

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)


Ovarian cancer is the sixth most common cancer and seventh most common cause of cancer death in women world-wide.Three-quarters of women present when the disease has spread through-put the abdomen (stage III or IV) and treatment consists of a combination of debulking surgery and platinum-based chemotherapy, with or without taxanes. Although initial responses to chemotherapy are often good, most women will relapse and require further chemotherapy and will eventually develop resistance to chemotherapy agents. Increased understanding about the molecular basis of ovarian cancer has lead to the development of novel agents, which work in different ways to conventional chemotherapy. These include DNA-repair pathway inhibitors, the commonest of which are the PARP (poly (ADP-ribose) polymerase) inhibitors. It is therefore important to compare their effectiveness and side effects of these novel agents to assess their role in the treatment of advanced ovarian cancer, especially as treatment of advanced disease is aiming to improve length of survival and quality of life (QoL).
Original languageEnglish
Pages (from-to)CD007929
JournalCochrane Database of Systematic Reviews
Issue number6
Publication statusPublished - 2010


Dive into the research topics of 'DNA-repair pathway inhibitors for the treatment of ovarian cancer'. Together they form a unique fingerprint.

Cite this